搜尋
Cytosorbents Corp
CTSO添加自選
0.391USD
+0.017+4.55%
收盤 07/01, 16:00（美東）報價延遲15分鐘
24.55M總市值
虧損本益比TTM
關鍵數據
0.395今開
0.410最高
178.82K成交量
虧損本益比TTM
10.35本益比動
--股利TTM
0.28%換手率
0.374昨收
0.382最低
63.99K成交額
虧損本益比靜
2.72市淨率
0.00%股息率 TTM
-25.94%ROA
1.39052週最高
0.68量比
-20.72M淨利潤
62.79M總股本
-0.1891每股盈餘TTM
1.37Beta
-141.59%ROE
0.43552週最低
7.57%振幅
69.16%毛利率
24.55M總市值
-4.68回報/風險
4.72%風險率
TradingKey Cytosorbents Corp股票評分
單位: USD 更新時間: 2026-06-30操作建議
Cytosorbents Corp當前公司基本面數據相對穩定，增長潛力較大。當前估值合理，在醫療設備與耗材行業排名127/204位。機構持股佔比非常高，近一月多位分析師給出公司評級為持有。最高目標價為2.88。中期看，股價處於下降通道。近一個月，市場表現非常差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Cytosorbents Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看空
Cytosorbents Corp亮點
亮點風險
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
業績高增長
公司營業收入穩步增長，連續3年增長19.23%
業績增長期
公司處於發展階段，最新年度總收入37.06M美元
估值高估
公司最新PE估值-1.98，處於3年歷史高位
機構減倉
最新機構持股16.20M股，環比減少5.98%
活躍度增加
近期活躍度增加，過去20天平均換手率0.98
分析師目標
基於
1
分析師
持有
評級
2.875
目標均價
+668.72%
漲幅空間
Cytosorbents Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Cytosorbents Corp簡介
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
公司代碼CTSO
公司Cytosorbents Corp
CEOChan (Phillip P)
網址https://cytosorbents.com/
相關品種
+2.62%
+2.41%
+1.57%
+1.18%
+1.73%
+1.30%
-0.50%
+1.27%
+7.60%
+0.88%
+0.39%
+0.89%
+1.92%
+1.70%
+3.09%
+2.12%
+1.08%
+1.78%
+0.41%
+0.78%熱門品種
52235.700
-18.600 (-0.04%)
29756.100
-43.200 (-0.14%)
7474.000
-1.500 (-0.02%)
15333.000
-22.000 (-0.14%)
68751.000
-734.000 (-1.06%)
6267.300
-8.100 (-0.13%)
67.754
-0.214 (-0.32%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4039.540
+8.770 (+0.22%)
常見問題
Cytosorbents Corp(CTSO)的當前股價是多少？
Cytosorbents Corp(CTSO)的當前股價是 0.39。
Cytosorbents Corp 的股票代碼是什麼？
Cytosorbents Corp的股票代碼是CTSO。
Cytosorbents Corp股票的52週最高點是多少？
Cytosorbents Corp股票的52週最高點是1.39。
Cytosorbents Corp股票的52週最低點是多少？
Cytosorbents Corp股票的52週最低點是0.43。
Cytosorbents Corp的市值是多少？
Cytosorbents Corp的市值是24.55M。
現在Cytosorbents Corp(CTSO)的股票是買入、持有還是賣出？
根據分析師評級，Cytosorbents Corp(CTSO)的總體評級為signal_hold，目標價格為2.88。
Cytosorbents Corp(CTSO)股票的每股收益（EPS TTM）是多少
Cytosorbents Corp(CTSO)股票的每股收益（EPS TTM）是-0.13。